Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024
Organogenesis Holdings (Nasdaq: ORGO), a leading regenerative medicine company, has announced it will report its second quarter fiscal year 2024 financial results on August 8, 2024, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Organogenesis Holdings (Nasdaq: ORGO), a leading regenerative medicine company, has announced it will report its second quarter fiscal year 2024 financial results on August 8, 2024, after market close. The company will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the results and provide a corporate update. Interested parties can access the live webcast or dial (800) 715-9871 with access code 6679912 to participate. The webcast will also be available on the company's investor relations website and archived for approximately one year.
Details
News Market Reaction – ORGO
The recorded move for ORGO in the trading session of this news was +6.92%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CANTON, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that second quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, August 8th.
Management will host a conference call at 5:00 p.m. Eastern Time on August 8th to discuss the results of the quarter and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or dial (800) 715-9871 and provide access code 6679912. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.